Exelixis, Inc. (ticker: EXEL, exchange: NASDAQ Global Market (.O))
News Release -
Exelixis Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Exelixis,
Inc. (Nasdaq: EXEL) announced today that it is offering to sell, subject to
market and other conditions, 9,000,000 shares of its common stock pursuant to
an effective shelf registration statement in an underwritten public offering.
Exelixis also intends to grant the underwriters a 30-day option to purchase up
to an additional 1,350,000 shares of common stock to cover over-allotments, if
any. All of the shares in the offering are to be sold by Exelixis.
Goldman, Sachs & Co. is acting as the sole book-running manager for the
offering. Cowen and Company, LLC is acting as the joint lead manager and Banc
of America Securities LLC and Piper Jaffray & Co. are acting as co-managers
for the offering.
A registration statement relating to these securities has been filed with
and declared effective by the Securities and Exchange Commission. The offering
may be made only by means of a prospectus supplement and the accompanying
prospectus. Copies of the preliminary prospectus supplement and the
accompanying prospectus may be obtained by sending a request to Goldman, Sachs
& Co., Attn: Prospectus Department, 85 Broad Street, New York, New York 10004,
Fax: (212) 902-9316 or Email at firstname.lastname@example.org .
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, any of the securities, nor shall there be any
sale of these securities, in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state.
Exelixis, Inc. is a biotechnology company dedicated to the discovery and
development of novel therapeutics that will potentially enhance the care and
lives of patients with cancer and other serious diseases.
SOURCE Exelixis, Inc.
/CONTACT: Frank Karbe, Chief Financial Officer, +1-650-837-7565, or
email@example.com, or Charles Butler, Director, Corporate Communications,
+1-650-837-7277, or firstname.lastname@example.org, both of Exelixis, Inc./
/Web site: http://www.exelixis.com/
CO: Exelixis, Inc.
IN: BIO MTC HEA
-- SFW105 --
9388 09/27/2006 16:13 EDT http://www.prnewswire.com